Kelly Financial Services’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,633
Closed -$7.63K 279
2024
Q2
$7.63K Hold
1,633
﹤0.01% 447
2024
Q1
$12.1K Hold
1,633
﹤0.01% 399
2023
Q4
$16.5K Hold
1,633
0.01% 336
2023
Q3
$12.7K Hold
1,633
0.01% 338
2023
Q2
$13.4K Hold
1,633
0.01% 330
2023
Q1
$11.8K Hold
1,633
0.01% 334
2022
Q4
$14.5K Hold
1,633
0.01% 290
2022
Q3
$20K Hold
1,633
0.01% 261
2022
Q2
$19.3K Hold
1,633
0.01% 257
2022
Q1
$31.1K Hold
1,633
0.01% 229
2021
Q4
$43.4K Hold
1,633
0.02% 194
2021
Q3
$67.1K Sell
1,633
-90,860
-98% -$4.98M 0.04% 134
2021
Q2
$1.63M Buy
92,493
+90,860
+5,564% +$3.36M 0.06% 88
2021
Q1
$68.6K Hold
1,633
0.04% 105
2020
Q4
$114K Hold
1,633
0.08% 62
2020
Q3
$45.8K Hold
1,633
0.03% 104
2020
Q2
$48.3K Hold
1,633
0.04% 93
2020
Q1
$32.4K Hold
1,633
0.04% 106
2019
Q4
$48.4K Hold
1,633
0.04% 85
2019
Q3
$37.1K Sell
1,633
-70
-4% -$1.73K 0.03% 101
2019
Q2
$42.1K Hold
1,703
0.04% 88
2019
Q1
$41.6K Buy
+1,703
New +$38.5K 0.05% 86

Other funds holding EDIT

Kelly Financial Services's EDIT Position: Q3 2024 in Review

Kelly Financial Services sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 1,633 shares — an estimated $7.63K sold.

Kelly Financial Services first reported a position in EDIT in Q1 2019 and held it in 22 quarters. The position peaked at $1.63M in Q2 2021. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Kelly Financial Services reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • Kelly Financial Services sold 1,633 Editas Medicine shares in Q3 2024, an estimated $7.63K.
  • Kelly Financial Services first reported a position in Editas Medicine in Q1 2019 and held it in 22 quarters.
  • Kelly Financial Services's Editas Medicine position peaked at $1.63M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.